Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) · Paroxysmal Hemoglobinuria · Sponsor: Apellis Pharmaceuticals, Inc.
The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).
This description comes directly from the study's public registry record.
Apellis Clinical Trial Information Line · 1-833-284-6361 (833-CT Info-1) · clinicaltrials@apellis.com
Always discuss trial participation with your own doctor first.
| Children's Hospital of Atlanta | Atlanta, Georgia, United States | Recruiting |
| Motol University Hospital | Prague, Czechia | Completed |
| Robert-Debré Hospital Paris | Paris, France | Not Yet Recruiting |
| Hospital Ampang | Ampang, Malaysia | Recruiting |
| Radboud University Hospital Nijmegen | Nijmegen, Netherlands | Completed |
| University Medical Center Utrecht | Utrecht, Netherlands | Recruiting |
| University Children's Hospital | Belgrade, Serbia | Recruiting |
| University Hospital Vall d'Hebron | Barcelona, Spain | Recruiting |
| University Hospital 12 de Octubre | Madrid, Spain | Recruiting |
| Phramongkutklao Hospital and College of Medicine | Bangkok, Thailand | Completed |
| Maharaj Nakorn Chiang Mai hospital | Chiang Mai, Thailand | Recruiting |
| St. Mary's Hospital | London, United Kingdom | Completed |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04901936